Trends of industry-leading biotechnology stocks during COVID-19

The 2019-nCoV coronavirus has significantly impacted the macroeconomic outlook for countries across world. biotechnology sector experienced a relatively positive stock price outlook, which corroborates trends exhibited by stocks in previous pandemics such as SARS (2003) and AH1N1 (2009). During COVID-19 pandemic, vaccine roll-out rates have been more efficient than any other companies today are combating time constraint to create vaccines. Gilead Sciences Inc. saw its shares rise 18% after developing first FDA-approved vaccine, 'remdesivir'. In contrast, AstraZeneca's fell 2.28% 2021 underwent investigations into blood-clotting side effects subsequent suspension from several countries. Companies mRNA vaccines like Moderna, BioNTech, Pfizer witnessed surges share prices ranging 10% 20%. Many newer biotech Genexie, Sanovi, OnoSec, Vaxart also developed COVID-19. Share volatile these less established companies. This paper observes how new technologies, staging clinical trials, obtaining FDA approvals, gaining publicity, complex factors profound impacts on of